DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
about
Safety and efficacy of azacitidine in myelodysplastic syndromesEpigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidineDecitabine in the treatment of myelodysplastic syndromesDNA and the chromosome - varied targets for chemotherapyEpimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesTrials with 'epigenetic' drugs: an update5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signalGenome-wide analysis in human colorectal cancer cells reveals ischemia-mediated expression of motility genes via DNA hypomethylationNewly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compoundsModeling of non-steroidal anti-inflammatory drug effect within signaling pathways and miRNA-regulation pathwaysRole of protein tyrosine phosphatases in cancerEpigenetic deregulation in pediatric acute lymphoblastic leukemia.Epigenetic changes in the myelodysplastic syndrome.Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.Nitric oxide: perspectives and emerging studies of a well known cytotoxinThe effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromesMutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapyA prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndromePharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.Cancer as a manifestation of aberrant chromatin structure.A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndromeAzacitidine in the management of patients with myelodysplastic syndromes.Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialThe effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndromeAberrant DNA methylation is a dominant mechanism in MDS progression to AML.Models of granulocyte DNA structure are highly predictive of myelodysplastic syndromeDecitabine in the treatment of acute myeloid leukemia in elderly patients.Enzymatic methylation of DNA in cultured human cells studied by stable isotope incorporation and mass spectrometry.The evolving landscape in the therapy of acute myeloid leukemia.TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicinActivity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion: A case report and literature review.
P2860
Q24596561-85A231A7-C369-4185-953C-B75B488E14FAQ24608659-62571D6C-9D4F-4D93-B9EF-3371A49902C6Q24641906-B0FB9943-E1BF-4241-904D-336A81B43F44Q24792540-CB32C62B-0B5F-44E0-8684-1C95E721F5A3Q26744080-A8EBBC6A-4034-4878-9850-0BA12D917AAEQ27000542-35CA2490-81E4-41B7-8C1A-DB489B39E16AQ28384242-B2D4A747-D854-4FBC-8BC1-CBA9A13D6882Q28391482-BE12BE21-84E6-4607-967E-45DDBF26EA83Q28477252-878A9133-164A-4A8E-B411-0A76D21ED245Q28535339-2A30BDEE-A2D6-437A-91A8-85748016C8C1Q28741003-56ABB845-FA07-46BF-A06C-31E33AADAFE9Q33740709-98F1C6B5-196B-432B-AB9C-2E0C3C5A0D3DQ33767309-0C020181-68BC-4952-9F53-970B48616CE3Q33903052-F0447C2F-5289-4CAD-B330-8BFA3397A154Q34061919-F53D8D41-C0AA-4606-85B2-F056B5CAFA5DQ34979774-72C47FF3-AA40-4D0E-B51C-A709B364FBDCQ35132953-29C4C536-D01C-4BFB-AF62-FCE958C5A1FAQ35265834-376DE1D0-4497-4EA9-9B01-01500CB8E238Q35752467-D5981B55-7C5A-46FF-9D69-ABED2A3B11FAQ36545229-47B35D52-1F1D-403E-8A17-12DA537336BBQ36651427-8E6CFB3A-1EE6-4C71-9EE2-52A8DBCF4EEFQ36689145-3D840141-36AB-485B-BD00-4772365CBACBQ36768610-FBCADEC8-ED02-4CCD-9A37-BB582135F72BQ36799188-AAE9F9F7-0F1B-43DC-BFD8-0991635BF7D6Q36934199-F51EEA55-E4E3-4A79-A948-C1D982A80AD8Q36934269-FB7FC244-9913-4E6F-BD77-AEBEEABD5B81Q37060639-AF782D94-C6E2-4682-A88E-A867BCE18007Q37086937-AEAAE2C2-C7EA-4812-9A50-C07A78C83A46Q37415850-1B0D6DBD-B838-4088-8C88-73DEDF392DE5Q37568244-4D0CCD7F-25F2-4BEC-A7A1-5AB758B83A8BQ37700733-BA8BF1D3-DD4F-4B57-9825-C02698D03FECQ38132064-DCA95F66-ECD7-47B4-BC71-E030C864FDF9Q38231548-0CB126D2-47C2-4098-90D1-8013D3132022Q41480926-83FC75DF-2519-47AE-A4C3-99BC95CFDE6AQ42695542-2844F671-293F-4B2E-BA56-B9E48CCC2AF6Q43105406-97AE6C84-F8FF-4E93-8803-8238914C0670Q55080752-72DF316F-C997-4A52-8972-63A01742EE8C
P2860
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
DNA methylation and demethylat ...... romes and secondary leukemias.
@ast
DNA methylation and demethylat ...... romes and secondary leukemias.
@en
type
label
DNA methylation and demethylat ...... romes and secondary leukemias.
@ast
DNA methylation and demethylat ...... romes and secondary leukemias.
@en
prefLabel
DNA methylation and demethylat ...... romes and secondary leukemias.
@ast
DNA methylation and demethylat ...... romes and secondary leukemias.
@en
P2093
P1433
P1476
DNA methylation and demethylat ...... dromes and secondary leukemias
@en
P2093
Giuseppe Leone
Maria Teresa Voso
Michael Lübbert
P304
P577
2002-12-01T00:00:00Z